Sirtex Medical Limited (SRX), a leading developer of targeted and
innovative cancer therapies, is pleased to announce the appointment of
Dr. John Reddington as President of Sirtex Medical, Inc. This
appointment is effective from March 3, 2008. Sirtex Medical, Inc. is the
United States sales and marketing operations of SRX and is based in
Wilmington, Massachusetts USA. Sirtex manufactures SIR-Spheres®
microspheres, the only FDA-approved microsphere therapy for colorectal
cancer that metastasizes to the liver.1
Dr. Reddington has over 20 years of diverse experience encompassing
marketing and sales, management, business development, discovery
research, pre-clinical testing and clinical trials with private and
public biotechnology companies. He has recently been a senior manager
with a U.S. publicly traded biotechnology company focusing on gene
therapy and small molecule products for cancer and cardiovascular
medicine.
“With a background in research and
development, strategic planning and senior management, Dr. Reddington
provides excellent credentials to lead our growth in the U.S. market,”
said Gilman Wong, CEO of Sirtex Medical Ltd. “He
delivers by providing a clear vision to staff and building productive
relationships with key opinion leaders, regulators and customers. We are
excited to have John join our growing company, and look forward to his
contributions as we continue to expand.”
1 Sirtex Medical Inc.’s
SIR-Spheres® microspheres are indicated for
the treatment of non-resectable metastatic colorectal cancer in
combination with intra-arterial FUDR chemotherapy. Information regarding
other disease states or agents in combination with this device that is
presented in peer-reviewed literature is different from the approved USA
labeling for SIR-Spheres.
About Selective Internal Radiation Therapy (SIRT) using SIR-Spheres
microspheres
Selective Internal Radiation Therapy (SIRT) is a novel treatment for
inoperable liver cancer that delivers high doses of radiation directly
to the site of tumors. In a minimally-invasive treatment, millions of
radioactive SIR-Spheres microspheres are infused via a catheter into the
liver where they selectively target liver tumors with a dose of internal
radiation up to 40 times higher than conventional radiotherapy, while
sparing healthy tissue.
Clinical trials have confirmed that liver cancer patients treated with
SIR-Spheres microspheres have response rates higher than with other
forms of treatment, resulting in increased life expectancy, greater
periods without tumor activity, and improved quality of life. SIRT has
been found to shrink liver tumors more than chemotherapy alone.
SIRT using SIR-Spheres microspheres is approved for use in Australia,
New Zealand, the United States of America (FDA approval), European Union
(CE Mark), Hong Kong, Malaysia, Singapore, Thailand, Israel and India.
SIRT is available in 140 treatment centers around the world, and more
than 6500 patients have been treated to date.
Approximately 90 physicians in the United States use Sirtex’s
SIR-Spheres microspheres in more than 86 medical centers. For more
information, visit www.sirtex.com.
® SIR-Spheres is a Registered Trademark of
Sirtex SIR-Spheres Pty Ltd
|